Historique
Périodique
Relative bioavailability of different buprenorphine formulations under chronic dosing conditions
(Biodisponibilité relative de différentes formules de buprénorphine dans des conditions d'administration chronique)
Auteur(s) :
STRAIN, E. C. ;
MOODY, D. E. ;
STOLLER, K. B. ;
WALSH, S. L. ;
BIGELOW, G. E.
Année
2004
Page(s) :
37-43
Langue(s) :
Anglais
Refs biblio. :
25
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
BUPRENORPHINE
;
NALOXONE
;
PHARMACOCINETIQUE
;
DOSE-REPONSE
;
TRAITEMENT DE MAINTENANCE
Note générale :
Drug and Alcohol Dependence, 2004, 74, (1), 37-43
Note de contenu :
fig.
Résumé :
ENGLISH :
Background: Buprenorphine is an approved medication for the treatment of opioid dependence. Three sublingual formulations have been used at various times during its development-a solution containing alcohol, tablets containing buprenorphine alone, and tablets containing buprenorphine plus naloxone. This study compared the relative buprenorphine bioavailability of these different formulations. Methods: Outpatient volunteers (N = 10) were maintained for 14 days of daily administration on each formulation; the dose of buprenorphine (8 mg) was constant across formulations. Blood samples were collected and tested for buprenorphine and norbuprenorphine concentrations after 7 and 14 days maintenance on each formulation. Serial samples were collected before and for 6 h after a daily dose of each formulation. Results: Peak buprenorphine concentrations (Cmax) and area under the curve (AUC) for the 6 h interval (AUCo-6) were highest for the solution and lowest for buprenorphine alone tablets; values for combination tablets were more similar to those for solution. Differences between formulations were less pronounced at day 14 than day 7. There was considerable between-subject variability in concentrations produced. Conclusions: These results suggest there may be greater bioavailability of buprenorphine/naloxone versus buprenorphine alone tablets, and that the bioavailability of buprenorphine from the former is very similar to that seen with solution after 2 weeks of stabilization on each formulation. (Review's abstract.)
Affiliation :
Dept. Psychiatr. Behav. Sci., J. Hopkins Univ. Sch. Med., 5510 Nathan Shock Drive, Baltimore, MD 21224
Etats-Unis. United States.
Etats-Unis. United States.